The United States is experiencing a surge in measles cases, reaching levels not seen in decades. This increase, coupled with declining vaccination rates, is driving researchers to develop pharmaceutical treatments for the virus and those most vulnerable to it.
The US is currently seeing its highest number of measles cases in decades, according to recent data. Researchers are responding by developing drugs to help individuals who contract the virus, as well as those particularly susceptible to severe illness.
The need for these treatments stems directly from a concerning trend: falling vaccination rates. As fewer people receive the measles vaccine, more become vulnerable to infection, leading to outbreaks and increased cases. The development of therapies is seen as a necessary step to mitigate the impact of this growing public health concern. While vaccines remain the most effective preventative measure, having treatment options will be crucial for those who contract the virus despite vaccination efforts or are unable to receive the vaccine.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy